SCHEDULE: AstraZeneca Maintains 8.3% Stake in Innate Pharma

AstraZeneca PLC, through its subsidiary MedImmune Limited, has reaffirmed its 8.3% beneficial ownership in Innate Pharma SA.

Summary

• AstraZeneca PLC and its wholly-owned subsidiary, MedImmune Limited, are reporting persons in this Amendment No. 1 to Schedule 13D.
• The reporting persons beneficially own 7,825,501 Ordinary Shares of Innate Pharma SA, which includes 1,565,001 Ordinary Shares represented by American Depositary Shares (ADSs).
• This ownership represents 8.3% of Innate Pharma SA's outstanding Ordinary Shares.
• The percentage ownership is calculated based on 93,719,323 Ordinary Shares of Innate Pharma SA outstanding as of December 31, 2025, as reported in Innate Pharma's Form 6-K filed on January 7, 2026.
• Neither the reporting persons nor any individuals listed on Schedule I have effected any transactions in Innate Pharma's Ordinary Shares or ADSs during the past 60 days.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update for Innate Pharma, as it confirms a stable and significant strategic investment from AstraZeneca, indicating continued confidence and potential for future collaboration.

Positives

• AstraZeneca's continued significant stake (8.3%) in Innate Pharma suggests ongoing strategic interest and potential for future collaboration or development.
• The stability of the ownership, with no transactions reported in the last 60 days, indicates a consistent long-term investment perspective from a major pharmaceutical company.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Innate Pharma SA's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that AstraZeneca's continued significant stake in Innate Pharma underscores the strategic importance of Innate Pharma's pipeline or technology within the biopharmaceutical sector, potentially signaling ongoing collaboration or a long-term investment perspective from a major industry player. Such a stable, substantial investment from a global pharmaceutical giant like AstraZeneca can be viewed positively by the market, suggesting validation of Innate Pharma's assets.

Comparison to Industry Standards

• StockSavvy.ai notes that this filing is an ownership disclosure and does not contain performance metrics for direct comparison to industry standards or specific comparable companies/projects.

Stakeholder Impact

• Shareholders of Innate Pharma SA may view AstraZeneca's continued 8.3% stake as a positive indicator of stability and potential strategic backing, which could support investor confidence.
• The relationship with a major pharmaceutical company like AstraZeneca could open doors for Innate Pharma in terms of research, development, and market access.

Key Dates

Keywords

AstraZeneca, Innate Pharma, MedImmune, Schedule 13D, Beneficial Ownership, Biotechnology, Pharmaceuticals, Equity Stake, SEC Filing, Ordinary Shares, ADSs